News & Updates
Filter by Specialty:
Dapagliflozin most effective in frail patients with heart failure
Treatment with dapagliflozin results in improvements in all outcomes, regardless of frailty status, among patients with symptomatic heart failure (HF) with reduced ejection fraction, reports a study. However, “more frail” patients have larger absolute reductions.
Dapagliflozin most effective in frail patients with heart failure
28 Apr 2022
Annual flu jab in HF patients may lower hospitalization, pneumonia risk
An annual influenza vaccination does not lower the risk of cardiovascular (CV) outcomes in patients with heart failure (HF), though it may reduce the risk of pneumonia and hospitalization, according to results of the IVVE study presented at ACC.22.
Annual flu jab in HF patients may lower hospitalization, pneumonia risk
27 Apr 2022
Novel drug helps optimize HFrEF therapy
In individuals receiving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy for heart failure with reduced ejection fraction (HFrEF), the novel potassium binder patiromer effectively reduced serum potassium levels, the DIAMOND trial suggests, thus optimizing a guideline-directed RAASi therapy for these patients.
Novel drug helps optimize HFrEF therapy
27 Apr 2022
Intensive urate lowering of little benefit to patients with erosive gout
A more intensive serum urate-lowering therapy falls short of improving bone erosion scores in patients with erosive gout, in addition to being associated with a high treatment burden, as shown in a study.
Intensive urate lowering of little benefit to patients with erosive gout
27 Apr 2022
Novel drug promising for paediatric Tourette syndrome
The experimental drug ecopipam helps minimize motor and phonic tics in children and adolescents with Tourette syndrome, in addition to being safe and well tolerated, according to the results of a phase 2b trial presented at the 2022 American Academy of Neurology’s Annual Meeting (AAN 2022).